Calciparine adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Calciparine
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Product name as reported

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 1,228 adverse event reports that name Calciparine. The name is as reporters wrote it. In these reports the drug is a suspect or interacting product.

In the same period, 1,609 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 24 reports in the 12 months to June 2026 and 23 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Calciparine is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

In April to June 2026, FDA received 6 reports that name Calciparine.
In January to March 2026, FDA received 6.
In April to June 2025, FDA received 19.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 141 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for all 1,228 reports.

The site keeps a term for a year only if two or more reports of that year record it.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 141 terms.

Reaction terms in the reports that name Calciparine, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,228 reports
Thrombocytopenialow platelets	166	13.5%
Anaemialow red blood cells	116	9.4%
Eosinophilia	80	6.5%
Haematomaa collection of blood under the skin or in tissue	77	6.3%
Acute kidney injurysudden loss of kidney function	73	5.9%
Shock haemorrhagic	62	5%
Drug interactionan interaction between medicines	60	4.9%
Rash maculo-papulara rash of flat and raised spots	52	4.2%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	51	4.2%
Cholestasis	48	3.9%
Heparin-induced thrombocytopenia	46	3.7%
Renal failurekidney failure	42	3.4%
Renal failure acute	41	3.3%
International normalised ratio increasedblood clotting slower than intended (raised INR)	40	3.3%
Toxic skin eruption	37	3%
Gastrointestinal haemorrhagebleeding in the stomach or bowel	36	2.9%
Condition aggravatedthe condition being treated got worse	35	2.9%
Melaenablack tarry stools	35	2.9%
Neutropenialow neutrophils, a type of white blood cell	35	2.9%
Muscle haemorrhage	34	2.8%
Haematoma muscle	27	2.2%
Rashskin rash	27	2.2%
Haemoglobin decreasedlow haemoglobin	26	2.1%
Off label useused for a purpose or in a way not on the label	26	2.1%
Pruritusitching	26	2.1%
Pyrexiafever	25	2%
Coma	24	2%
Hypotensionlow blood pressure	24	2%
Encephalopathy	23	1.9%
Rectal haemorrhage	22	1.8%
Hepatic cytolysis	20	1.6%
Hepatocellular injury	20	1.6%
Cerebrovascular accidentstroke	19	1.5%
Haemorrhagebleeding	19	1.5%
Erythemaskin redness	18	1.5%
Haematuriablood in the urine	18	1.5%
Acute generalised exanthematous pustulosis	16	1.3%
Acute motor-sensory axonal neuropathy	16	1.3%
Falla fall	16	1.3%
Hypertransaminasaemia	16	1.3%
Rhabdomyolysismuscle breakdown	16	1.3%
Toxic epidermal necrolysisa severe skin reaction with peeling	16	1.3%
Overdosea dose above the recommended amount	15	1.2%
Epistaxisnosebleed	14	1.1%
Sepsisa severe body-wide response to infection	14	1.1%
Cardiac failureheart failure	13	1.1%
Faeces discoloured	13	1.1%
Haematemesis	13	1.1%
Hypokalaemialow blood potassium	13	1.1%
Pancytopenialow counts of all blood cells	13	1.1%

Download all 141 terms of Calciparine (CSV)

The counts add to more than 1,228 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Calciparine, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2004	17	17	1	2	16	0	1	0
2005	19	19	7	2	17	0	2	0
2006	13	13	2	1	11	0	5	0
2007	24	24	4	6	18	0	1	0
2008	40	40	11	3	34	1	4	0
2009	33	33	3	7	27	0	9	0
2010	40	40	9	7	31	1	12	0
2011	55	55	20	10	33	0	10	0
2012	48	48	5	8	40	0	8	0
2013	48	48	10	6	34	0	11	0
2014	46	46	6	5	35	1	14	0
2015	53	53	6	7	37	1	19	0
2016	71	71	12	8	55	0	29	0
2017	60	60	10	4	48	0	25	0
2018	146	145	31	22	89	1	75	1
2019	149	149	15	30	68	0	80	0
2020	102	102	17	26	47	0	51	0
2021	57	56	9	4	21	0	31	1
2022	46	46	4	1	37	0	27	0
2023	63	63	16	3	41	0	35	0
2024	38	38	4	4	26	0	30	0
2025	45	45	2	11	24	0	23	0
2026	15	15	0	0	11	0	8	0

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Calciparine, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Calciparine, by the year in which FDA received them
Year	Reports
2004	15
2005	21
2006	11
2007	26
2008	40
2009	34
2010	40
2011	54
2012	56
2013	51
2014	65
2015	39
2016	74
2017	72
2018	144
2019	130
2020	114
2021	53
2022	58
2023	61
2024	25
2025	33
2026	12

Reports that name Calciparine, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Calciparine
Age	Reports	Share
Under 2	7	0.6%
2 to 11	0	0%
12 to 17	0	0%
18 to 44	43	3.5%
45 to 64	196	16%
65 to 74	274	22.3%
75 and over	581	47.3%
Age not given	127	10.3%

Sex of the patient in the reports that name Calciparine
Sex	Reports	Share
Female	536	43.6%
Male	630	51.3%
Unknown or not given	62	5%

Type of reporter in the reports that name Calciparine
Reporter	Reports	Share
Physician	463	37.7%
Pharmacist	180	14.7%
Other health professional	405	33%
Lawyer	0	0%
Consumer or non-health professional	131	10.7%
Not given	49	4%

Age and sex are as the report gives them. The reporter is the primary source in the report. 0.5% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Calciparine record
Indication as recorded (MedDRA)	Reports	Share
Thrombosis prophylaxis	270	22%
Atrial fibrillation	100	8.1%
Prophylaxis	79	6.4%
Anticoagulant therapy	57	4.6%
Deep vein thrombosis	41	3.3%
Pulmonary embolism	27	2.2%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,228 reports.

Pages near this one

Calan next in the A to Z list
Calcipotriene next in the A to Z list
Caffeine citrate next in the A to Z list
Calcitonin next in the A to Z list
Caffeine next in the A to Z list
Calcitonin salmon next in the A to Z list
Caelyx next in the A to Z list
Calcitriol next in the A to Z list
Caduet next in the A to Z list
Calcium next in the A to Z list
Cabozantinib next in the A to Z list
Calcium acetate next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for CalciparineThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Calciparine: adverse event reports that FDA received. https://reportedreactions.com/drug/calciparine/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Calciparine as a suspect or interacting product. The 1,609 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Calciparine was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Calciparine?

No. It is a count of what people reported to FDA: 1,228 reports from February 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Physician (37.7%), other health professional (33%) and pharmacist (14.7%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page